title: Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study.
abstract: The treatment options for psoriasis in HIV-infected individuals are limited due to the immunosuppressive nature of the therapeutic modalities and the patient's immunocompromised state. Etanercept has been shown to be safe and effective in the non-HIV psoriasis population with nearly 20 years of experience. However, there is limited data on the safety of etanercept use in the HIV patient population. The authors report a case of an HIV-infected patient with psoriasis who has remained mostly clear on continuous, uninterrupted etanercept use for over six years.
authors.affiliation: University of California, San Francisco, Department of Dermatology, USA. ericslee@gmail.com
authors.forename: Eric S
authors.initials: ES
authors.lastname: Lee
authors.forename: Misha M
authors.initials: MM
authors.lastname: Heller
authors.forename: Faranak
authors.initials: F
authors.lastname: Kamangar
authors.forename: Kelly K
authors.initials: KK
authors.lastname: Park
authors.forename: John Y M
authors.initials: JY
authors.lastname: Koo
mesh_terms: D000328:Adult; D000068800:Etanercept; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept